Drug classification and characteristics of Maribavir/Yitazhi

Maribavir (Maribavir) is a new type of antiviral drug that is a selective UL97 protein kinase inhibitor. It is the first drug in the anti-cytomegalovirus (CMV) drug family that works through this target mechanism. Its unique molecular structure and targeting mechanism make it pharmacologically classified as a "direct-acting antiviral drug (DAA)", which is different from traditional nucleotide analog drugs. Maribavir blocks the activity of UL97 kinase and inhibits the key phosphorylation steps in the packaging and replication process of viral DNA, fundamentally cutting off the life cycle of the virus in the host cell.

In terms of pharmacokinetics, maribavir has a high oral absorption rate and a plasma protein binding rate exceeding 95%. It is mainly metabolized by CYP3A4 and excreted in the feces. The drug has a moderate half-life, allowing it to be administered twice daily to maintain stable blood concentrations, thereby effectively controlling viral replication. Compared with traditional CMV drugs, maribavir does not cause significant renal function damage or bone marrow suppression, which is especially suitable for transplant patients who receive long-term immunosuppressants.

In terms of drug properties, maribavivir has three major advantages: high selectivity, low toxicity, and strong inhibitory activity against drug-resistant strains. It does not compete with CMV DNA polymerase for binding, thus avoiding the common cross-resistance problem of ganciclovir drugs. Clinical application data show that maribavir can significantly improve the virus clearance rate and improve the quality of life of patients in the treatment of drug-resistant or recurrent CMV infection.

In addition, the dosage form of maribabavir tablets is stable and can be administered orally, which facilitates long-term maintenance treatment. The drug is widely distributed in the body and can quickly reach infected tissues, helping to reduce the risk of viral latency and reactivation. It is worth noting that its safety characteristics make it an important part of the current CMV treatment regimen and has been included in the recommendations of clinical guidelines in many countries.

Reference materials:https://www.livtencity.com/